MK-677 (Ibutamoren) is one of the most-discussed orally active growth-hormone secretagogues in the research literature. This article summarises what published, peer-reviewed studies actually report about its effect on the GH/IGF-1 axis, body composition, bone turnover and sleep, alongside its regulatory status. It is written for laboratory and educational reference only.
What is MK-677 (Ibutamoren)?
MK-677, also called Ibutamoren or L-163,191, is a non-peptide, orally active agonist of the growth hormone secretagogue receptor (the ghrelin receptor). By mimicking ghrelin, it stimulates the pituitary gland to release growth hormone (GH) in a pulsatile pattern, which in turn raises circulating insulin-like growth factor 1 (IGF-1). Unlike injectable peptides, it is studied at the bench as a once-daily oral compound because of its relatively long half-life. It remains an investigational research chemical and is not an approved medicine.
How does MK-677 work on the GH/IGF-1 axis?
Ibutamoren acts on the ghrelin/GH-secretagogue receptor rather than directly supplying growth hormone. In a 1996 study by Chapman and colleagues in healthy elderly subjects, two weeks of oral MK-677 increased mean 24-hour GH concentrations in a dose-dependent way, and serum IGF-1 rose into the range typical of young adults. Importantly, the data indicated the compound enhanced the amplitude of natural GH pulses rather than overriding the body's feedback loops, which is the central mechanistic feature researchers reference.
What does the research show about body composition?
The most cited long-term data come from a two-year, double-blind, randomised, placebo-controlled trial by Nass and colleagues (2008) in 65 healthy adults aged 60-81. Daily oral MK-677 raised GH and IGF-1 toward young-adult levels and increased fat-free mass relative to placebo (a change of roughly +1.1 kg versus -0.5 kg). However, the same trial recorded increases in fasting blood glucose and a reduction in insulin sensitivity, and it did not demonstrate gains in muscle strength or function. These mixed findings are an important part of any neutral summary.
What does the research show about bone and sleep markers?
Bone turnover has also been examined. A 1999 analysis by Murphy and colleagues pooled 187 elderly adults across three randomised, placebo-controlled studies and found MK-677 raised markers of both bone formation (osteocalcin, bone-specific alkaline phosphatase) and bone resorption. Separately, early pharmacology reports noted changes in self-reported and measured sleep parameters. Researchers generally treat these as preliminary signals that establish biological activity rather than proof of any clinical benefit.
How does MK-677 compare with injectable GH peptides?
A common point of confusion is how an oral secretagogue differs from injectable growth-hormone-releasing peptides. The table below summarises mechanistic differences referenced in the literature. It is provided for educational comparison only and is not a recommendation of use.
| Attribute | MK-677 (Ibutamoren) | Injectable GH-releasing peptides (e.g. GHRP class) |
|---|---|---|
| Chemical class | Non-peptide small molecule | Short peptide chains |
| Route in research protocols | Orally active | Subcutaneous injection |
| Receptor target | Ghrelin / GH-secretagogue receptor | Ghrelin and/or GHRH receptors (varies) |
| Half-life profile | Relatively long; studied once daily | Generally short; often dosed multiple times |
| Mechanism | Amplifies natural pulsatile GH release | Stimulates GH release via peptide signalling |
| Regulatory status | Not an approved medicine; research-only | Mostly not approved medicines; research-only |
Is MK-677 legal or approved in the UK?
MK-677 has not been approved as a medicine by the MHRA, EMA or FDA and has not completed the clinical evaluation required for human therapeutic use. It is supplied strictly as a research chemical for laboratory and educational purposes and is not a dietary supplement or a product for human consumption. The FDA has issued warning letters to companies marketing it for human use. In sport, ibutamoren is prohibited at all times by the World Anti-Doping Agency under the S2 peptide hormones and growth-factor category, so it is banned for tested athletes.
Why does product quality and testing matter?
Because MK-677 is widely referenced, it is also frequently mislabelled or underdosed by low-quality sellers, which undermines any research that relies on it. For laboratory work, identity and purity verification through independent third-party analysis is the most important quality signal. Every Free Muscle batch is third-party tested - you can review the certificates of analysis on the Lab Tests page, and the research listing is available here.
Research references
- Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. doi:10.1210/jcem.81.12.8954023 (PMID: 8954023)
- Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 1999;14(7):1182-1188. doi:10.1359/jbmr.1999.14.7.1182 (PMID: 10404019)
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003 (PMID: 18981485)
For laboratory and educational research purposes only. MK-677 is not an approved medicine, has not been evaluated by the MHRA, EMA or FDA, and is not for human consumption or therapeutic use. Nothing here is medical advice or a claim of benefit.